Back to Search
Start Over
Role of B cells in immune‐related adverse events following checkpoint blockade.
- Source :
-
Immunological Reviews . Sep2023, Vol. 318 Issue 1, p89-95. 7p. - Publication Year :
- 2023
-
Abstract
- Summary: Blockade of immune checkpoints has transformed the therapy of several cancers. However, immune‐related adverse events (irAEs) have emerged as a major challenge limiting the clinical application of this approach. B cells are recognized as major players in the pathogenesis of human autoimmunity and have been successfully targeted to treat these disorders. While T cells have been extensively studied as therapeutic targets of immune checkpoint blockade (ICB), these checkpoints also impact B cell tolerance. Blockade of immune checkpoints in the clinic is associated with distinct changes in the B cell compartment that correlate with the development of irAEs. In this review, we focus on the possible role of humoral immunity, specifically human B cell subsets and autoantibodies in the pathogenesis of ICB‐induced irAEs. There remains an unmet need to better understand the T:B cell cross talk underlying the activation of pathogenic B cells and the development of ICB‐induced irAEs. Such studies may identify new targets or approaches to prevent or treat irAEs and improve the application of ICB therapy in cancer. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01052896
- Volume :
- 318
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Immunological Reviews
- Publication Type :
- Academic Journal
- Accession number :
- 172301877
- Full Text :
- https://doi.org/10.1111/imr.13238